Tango Therapeutics Unveils Pipeline Advancements Targeting MTAP-Deleted Cancers

Reuters01-14

Tango <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Pipeline Advancements Targeting MTAP-Deleted Cancers

Tango Therapeutics Inc. has provided an update on its clinical pipeline targeting multiple high-value cancer indications. The company highlighted vopimetostat as a potentially best-in-class PRMT5 inhibitor, with clinical data supporting its use in various MTAP-deleted cancers, including pancreatic and lung cancer. Tango is preparing to launch a pivotal study of vopimetostat in second-line MTAP-deleted pancreatic cancer and has initiated combination studies with RAS inhibitors for MTAP-deleted/RAS-mutant pancreatic and lung cancers. Additional pipeline advancements include a brain-penetrant PRMT5 inhibitor, TNG456, in phase 1/2 development for glioblastoma, and TNG961, which is IND-ready for multiple MTAP-deleted/FOCAD-deleted solid tumors. The company reported a cash balance of $343 million as of December 31, 2025, with a projected runway into 2028. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603657120?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603657120","market":"us","top_or_hot":-1,"title":"Tango Therapeutics Unveils Pipeline Advancements Targeting MTAP-Deleted Cancers","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tango <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Pipeline Advancements Targeting MTAP-Deleted Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TNGX\">Tango Therapeutics Inc.</a> has provided an update on its clinical pipeline targeting multiple high-value cancer indications. The company highlighted vopimetostat as a potentially best-in-class PRMT5 inhibitor, with clinical data supporting its use in various MTAP-deleted cancers, including pancreatic and lung cancer. Tango is preparing to launch a pivotal study of vopimetostat in second-line MTAP-deleted pancreatic cancer and has initiated combination studies with RAS inhibitors for MTAP-deleted/RAS-mutant pancreatic and lung cancers. Additional pipeline advancements include a brain-penetrant PRMT5 inhibitor, TNG456, in phase 1/2 development for glioblastoma, and TNG961, which is IND-ready for multiple MTAP-deleted/FOCAD-deleted solid tumors. The company reported a cash balance of $343 million as of December 31, 2025, with a projected runway into 2028. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tango Therapeutics Unveils Pipeline Advancements Targeting MTAP-Deleted Cancers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTango Therapeutics Unveils Pipeline Advancements Targeting MTAP-Deleted Cancers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-14 10:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tango <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Pipeline Advancements Targeting MTAP-Deleted Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TNGX\">Tango Therapeutics Inc.</a> has provided an update on its clinical pipeline targeting multiple high-value cancer indications. The company highlighted vopimetostat as a potentially best-in-class PRMT5 inhibitor, with clinical data supporting its use in various MTAP-deleted cancers, including pancreatic and lung cancer. Tango is preparing to launch a pivotal study of vopimetostat in second-line MTAP-deleted pancreatic cancer and has initiated combination studies with RAS inhibitors for MTAP-deleted/RAS-mutant pancreatic and lung cancers. Additional pipeline advancements include a brain-penetrant PRMT5 inhibitor, TNG456, in phase 1/2 development for glioblastoma, and TNG961, which is IND-ready for multiple MTAP-deleted/FOCAD-deleted solid tumors. The company reported a cash balance of $343 million as of December 31, 2025, with a projected runway into 2028. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNGX","symbol_name":"Tango Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL9WRYLQ:1","article_id":"2603657120","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603657120","pubTimestamp":1768356135,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tango Therapeutics Inc. has provided an update on its clinical pipeline targeting multiple high-value cancer indications. The company highlighted vopimetostat as a potentially best-in-class PRMT5 inhibitor, with clinical data supporting its use in various MTAP-deleted cancers, including pancreatic and lung cancer. Tango is preparing to launch a pivotal study of vopimetostat in second-line MTAP-deleted pancreatic cancer and has initiated combination studies with RAS inhibitors for MTAP-deleted/RAS-mutant pancreatic and lung cancers. Additional pipeline advancements include a brain-penetrant PRMT5 inhibitor, TNG456, in phase 1/2 development for glioblastoma, and TNG961, which is IND-ready for multiple MTAP-deleted/FOCAD-deleted solid tumors. The company reported a cash balance of $343 million as of December 31, 2025, with a projected runway into 2028. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generati","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNGX":"Tango Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"Tango Therapeutics公布针对MTAP缺失癌症的管道进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNGX":0.9},"content_text":"Tango Therapeutics Unveils Pipeline Advancements Targeting MTAP-Deleted Cancers\n    \n\nTango Therapeutics Inc. has provided an update on its clinical pipeline targeting multiple high-value cancer indications. The company highlighted vopimetostat as a potentially best-in-class PRMT5 inhibitor, with clinical data supporting its use in various MTAP-deleted cancers, including pancreatic and lung cancer. Tango is preparing to launch a pivotal study of vopimetostat in second-line MTAP-deleted pancreatic cancer and has initiated combination studies with RAS inhibitors for MTAP-deleted/RAS-mutant pancreatic and lung cancers. Additional pipeline advancements include a brain-penetrant PRMT5 inhibitor, TNG456, in phase 1/2 development for glioblastoma, and TNG961, which is IND-ready for multiple MTAP-deleted/FOCAD-deleted solid tumors. The company reported a cash balance of $343 million as of December 31, 2025, with a projected runway into 2028. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603657120","isCrawlerRequest":true}